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Background and PurposeaaMutations of the skeletal muscle sodium channel gene SCN4A, 
which is located on chromosome 17q23-25, are associated with various neuromuscular disorders 
that are labeled collectively as skeletal muscle sodium channelopathy. These disorders include 
hyperkalemic periodic paralysis (HYPP), hypokalemic periodic paralysis, paramyotonia conge-
nita (PMC), potassium-aggravated myotonia, and congenital myasthenic syndrome. This study 
analyzed the clinical and mutational spectra of skeletal muscle sodium channelopathy in Korean 
subjects. 
MethodsaaSix unrelated Korean patients with periodic paralysis or nondystrophic myotonia 
associated with SCN4A mutations were included in the study. For the mutational analysis of 
SCN4A, we performed a full sequence analysis of the gene using the patients’ DNA. We also an-
alyzed the patients’ clinical history, physical findings, laboratory tests, and responses to treatment. 
ResultsaaWe identified four different mutations (one of which was novel) in all of the patients 
examined. The novel heterozygous missense mutation, p.R225W, was found in one patient with 
mild nonpainful myotonia. Our patients exhibited various clinical phenotypes: pure myotonia 
in four, and PMC in one, and HYPP in one. The four patients with pure myotonia were initially 
diagnosed as having myotonia congenita (MC), but a previous analysis revealed no CLCN1 
mutation. 
ConclusionsaaClinical differentiating between sodium-channel myotonia (SCM) and MC is 
not easy, and it is suggested that a mutational analysis of both SCN4A and CLCN1 is essential 
for the differential diagnosis of SCM and MC.  J Clin Neurol  2009;5:186-191
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Introduction 
 
The skeletal muscle sodium channel comprises a principal 
pore-forming and voltage-sensing subunit (the alpha subunit), 
which is associated with an accessory beta-1 subunit. Its 
alpha subunit is encoded by the gene SCN4A, which is lo-
cated on chromosome 17q23-25,
1 comprises 24 exons with a 
5.5-kb open reading frame,
2 and is associated with various 
neuromuscular disorders. The beta-1 subunit has not been 
reported to be linked to any human disease. 
More than 40 different types of SCN4A mutation have been 
identified, most of which are single-base substitutions pro-
ducing missense mutations.
3 In contrast to the chloride and 
calcium channelopathies, which produce relatively uniform 
phenotypes, SCN4A mutations produce several clinically dis-
tinct skeletal muscle disorders including hyperkalemic pe-
riodic paralysis (HYPP), paramyotonia congenita (PMC), po-
tassium-aggravated myotonia (PAM), hypokalemic periodic 
paralysis, and congenital myasthenic syndrome.
4-8 Previous 
studies have also shown that certain SCN4A mutations are 
associated with a specific phenotype, and it has been sug-
gested that the mutation-specific differences in aberrant ch-
annel gating behavior underlies the genotype-phenotype cor-
relation in skeletal muscle sodium channelopathy.
9 
In this context, we studied six Korean patients with SCN4A 
mutations who showed various clinical types of nondystro- 
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phic myotonia and periodic paralysis syndromes. We rea-
soned that this would help to clarify the genotype-phenotype 
correlations in Korean patients with this group of disorders. 
We therefore performed a mutational analysis of SCN4A in 
these patients, and analyzed their clinical features in detail. 
 
Methods 
 
Subjects 
Six unrelated Korean patients with nondystrophic myotonia 
and periodic paralysis syndrome were included in the study. 
The patients comprised one patient with HYPP, one with 
PMC, and four with pure myotonia. Mutation of CLCN1 had 
previously been excluded in all four patients with the pure 
myotonia phenotype, by full sequence analysis of its coding 
regions.
10 The control group comprised 100 healthy Koreans. 
All of the patients and controls provided written informed 
consent to participate in this study, which was reviewed and 
approved by the Pusan National University Hospital Insti-
tutional Review Board. 
 
Clinical evaluation 
A detailed clinical history was taken from all patients, and all 
underwent a standard neurological examination. History-tak-
ing revealed several clinical data, including age of onset, first 
clinical symptom, the most disabling symptom at the time of 
presentation, and family history. On neurological examina-
tion, special notice was taken of the presence of muscle atro-
phy or hypertrophy, distribution of muscle weakness (if any), 
status of the deep-tendon reflexes, and types of maneuver 
that provoke myotonia. All patients submitted to electrodiag-
nostic studies, including routine nerve conduction studies and 
needle electromyography (EMG) from at least two different 
muscles in each extremity. Routine laboratory tests were per-
formed, including complete blood count, liver and renal func-
tion tests, thyroid function tests, blood glucose, electrolytes, 
serum creatine kinase levels, chest X-ray, and electrocardio-
gram. Muscle biopsy procedures were performed in three pa-
tients. The biopsied muscle samples were flash frozen in iso-
pentane prechilled with liquid nitrogen and then processed 
for routine histochemical reactions including hematoxylin-
eosin, modified Gomori trichrome, NADH, and ATPase stains. 
 
DNA analysis 
The SCN4A mutations were identified by direct sequence 
analysis of whole coding regions of the gene. DNA was ex-
tracted from the patients’ anticoagulated whole blood, and 21 
sequence specific primer pairs covering the entire coding re-
gion of SCN4A were subjected to PCR amplification. Primer 
sequence data and information on the PCR conditions are 
available upon request. 
The amplified PCR products were separated on 2% aga-
rose gels, purified, cycle-sequenced with PCR primers using 
the BigDyeTerminator Sequencing Kit (PE Applied Biosys-
tems, Foster, CA, USA), and electrophoresed using an ABI 
PRISM 3730XL DNA analyzer (PE Applied Biosystems). 
PCR-restriction fragment length polymorphism (RFLP) 
was conducted on patient 3 and the 100 normal controls to 
confirm the presence of the novel c.673C>T (p.R225W) mu-
tation found in this patient and to establish that it is not a 
benign polymorphism. The mutation was identified using the 
restriction enzyme Aci I to discriminate the mutated allele 
from normal alleles. The primer pair 5’-TGCACTGTCCT 
TCCCAACCC-3’ (forward) and 5’-GCCTCTCAAACGCC 
CATCCT-3’ (reverse) was used for the PCR reaction. Since 
the mutated allele will lose the normal Aci I restriction site, a 
heterozygous mutation of c.673C>T will produce three DNA 
bands at 472, 245, and 227 bp, while normal alleles will pro-
duce bands at only 245 and 227 bp. All enzyme digestion re-
actions were conducted at 37℃ for 2 hours, and the electro-
phoresis was performed on 2% agarose gel. 
 
Results 
 
SCN4A mutations 
The sequence analysis revealed four different mutations in-
Outside
Inside
NH3
p.lle693Thr 
p.Ala1156Thr 
p.Gly1306Glu 
p.Arg225Trp  COOH 
I  II  III  IV 
Fig. 1. Membrane-folding model of the sodium channel
alpha subunit and locations of the missense mutations
identified in the present study. A novel mutation, p.Arg
225Trp, is located at the transmembrane S3 segment of
domain I.  
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cluding one that has not been described previously. The types 
and locations of the identified mutations are summarized in 
Figs. 1 and 2, and Table 1. A novel missense mutation, c.673C> 
T, was identified in exon 5 from patient 3, which is expected 
to change a codon for arginine into tryptophan at position 225 
(p.R225W). This is considered a pathogenic mutation because 
1) we were unable to observe the same alteration in any of 
the 100 normal controls using PCR-RFLP analysis (Fig. 3A), 
and 2) the mutated amino acid arginine at position 225 is 
highly conserved between different species in multiple align-
ment analysis of the amino acid sequence (Fig. 3B). 
Two patients (patients 2 and 5) shared a c.3466G>A (p.A 
1156T) mutation in exon 19, and another mutation in exon 
22 (c.3917G>A, p.G1306E) was shared by two other patients 
(patients 1 and 6). In patients 4, the mutation c.2078T>C 
(p.I693T) was identified in exon 13 (Table 1, Figs. 1 and 2). 
 
Clinical features 
The clinical features of the six patients are summarized in 
Table 2. They comprised six men with ages of onset from 
birth to 30 years. The four patients with the pure myotonia 
phenotype (patients 1, 2, 3, and 6) had myotonia with the 
warm-up phenomenon, which initially affected predominantly 
the lower extremities. In this group of patients, muscle stiff-
ness was provoked by voluntary contraction of the skeletal 
muscles after a period of rest, and typical myotonic disch-
arges were observed on EMG. Patient 4 presented with myo-
tonia that worsened by repetitive exercise and cold exposure, 
and was classified as having the PMC phenotype. EMG in 
this patient also revealed prominent myotonic discharges. Pe-
riodic weakness was the main symptom in patient 5, together 
with elevated serum potassium levels. Needle EMG also re-
vealed myotonic discharges. 
 
Discussion 
 
We have identified four different SCN4A mutations (one of 
which has not been reported previously) in six unrelated Ko-
rean patients with nondystrophic myotonia and periodic pa-
ralysis syndrome. A novel heterozygous missense mutation 
c.673C>T (p.R225W) was found in patient 3, who presented 
with mild nonpainful pure myotonia (Table 1 and 2). This 
mutation is located at the cytoplasmic side of transmembrane 
S3 segment of domain I (DI/S3; Figs. 1 and 2), and is no-
teworthy because most of the previously reported SCN4A 
Table 1. SCN4A mutations identified in the study 
Change in 
nucleotide 
Change in 
codon 
Change in 
amino acid 
Site 
Patient 
numbers 
c.673C>T  CGG>TGG p.R225W  Exon  5  3 
c.2078T>C ATT>ACT  p.I693T  Exon  13  4 
c.3466G>A  GCC>ACC  p.A1156T  Exon 22  2, 5 
c.3917G>A  GGG>GAG  p.G1306E  Exon 21  1, 6 
 
A B
C D
Fig. 2. Chromatograms of the patients. A: A novel mutation in exon 5 was identified in patient 3. A substitution of cytosine to thymidine at
position 673 changes the codon for arginine at position 225 into tryptophan. B: A substitution of thymidine to cytosine at position 2078 in
patient 4 changes the codon for isoleucine at position 693 into threonine. C: A substitution of guanine to adenine at position 3466 in patients
2 and 5 changes the codon for alanine at position 1156 into threonine. D: A substitution of guanine to adenine at position 3917 in patients 1
and 6 changes the codon for glycine at position 1306 into glutamate.  
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Table 2. Summary of patients’ clinical findings 
Patient 
number 
Gender 
Age 
(years) 
Age at first 
symptom 
(years) 
Affected 
family 
Clinical features  Phenotype 
SCN4A 
mutation 
1 Male  21  Birth  (–)  Painful myotonia with warm-up phenomenon involving 
  the face and extremities; excessive sweating in the 
  hands and soles; intermittent mild subjective 
 generalized  weakness; generalized muscular 
 hypertrophy; no cold sensitivity 
Pure 
Myotonia 
p.G1306E 
2 Male  33  30  (–)  Relatively mild, nonpainful myotonia with warm-up 
  phenomenon involving the posterior legs; 
  no muscle hypertrophy; no cold sensitivity 
Pure 
myotonia 
p.A1156T 
3 Male  21  11  (–)  Nonpainful myotonia with warm-up phenomenon 
  involving the lower extremities; myotonia is provoked 
  by cold exposure and associated with transient 
 weakness; no muscle hypertrophy 
Pure 
myotonia 
p.R225W 
4 Male  07  05  (–)  Myotonia worsened by repetitive exercise; 
  myotonic stiffness in the extremities; generalized 
 muscular  hypertrophy; no transient weakness 
PMC p.I693T 
5 Male  28  27  (–)  Periodic profound generalized muscle weakness lasting 
  a few days associated with hyperkalemia; intermittent 
  short-lasting muscle weakness after strenuous exercise; 
  no clinical myotonia; generalized weakness was 
  induced by potassium loading 
HYPP p.A1156T 
6 Male  32  Childhood  (+)  Nonpainful myotonia with warm-up phenomenon; 
  affects the face and extremities; generalized muscular 
 hypertrophy; no transient weakness; no cold sensitivity; 
  a son and a daughter are also affected 
Pure 
myotonia 
p.G1306E 
PMC: paramyotonia congenita, HYPP: hyperkalemic periodic paralysis.   
Fig. 3. A: The results of PCR-restriction 
fragment length polymorphism using res-
triction enzyme Aci I for the identifica-
tion of the novel c.673C>T (p.Arg225Trp)
mutation. No similar digestion pattern
was observed among 100 normal con-
trol chromosomes. M, 100-bp molecular 
marker; U, undigested PCR product from 
patient 3; P, patient 3; numbers, control.
B: Multiple alignment of the homologous 
sodium channel alpha subunit protein
between different species of eukaryotes. 
The mutated protein in patient 3 (p.Arg
225Trp, arrowheads) is highly conserv-
ed between species. 
M   U  P   1   2    3   4    5   6    7   8    9  10   11   12   13   14   15   16   17   18   19  20   21   22 
245 bp 
227 bp 
bp 
Homo sapiens
Mus musculus
Rattus novegicus
Canis familiaris
Danio rerio
Homo sapiens
Mus musculus
Rattus novegicus
Canis familiaris
Danio rerio
Homo sapiens
Mus musculus
Rattus novegicus
Canis familiaris
Danio rerio
130             140             150             160             170             180 
190             200             210             220  2 3 0              2 4 0  
250             260             270             280  2 9 0              3 0 0  
A 
B  
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mutations are clustered in domains III or IV of the protein. 
Furthermore, it is the most proximal mutation ever reported 
in SCN4A. Thus far only two mutations affecting domain I 
have been reported.
11,12 This mutation is also remarkable be-
cause there is only one previous report of an SCN4A mu-
tation affecting the S3 segment (p.L1433R).
13 
Another mutation, c.2078T>C (p.I693T), was identified in 
patient 4, who exhibited a typical PMC phenotype. This mu-
tation is located at the cytoplasmic link between S4 and S5 of 
DII, and has been reported previously in patients with PMC 
(Table 1, Figs. 1 and 2).
14  
The c.3466G>A (p.A1156T) mutation was shared by two 
of our patients who exhibited completely different pheno-
types (Table 1, Figs. 1 and 2): while patient 2 had pure myo-
tonia affecting the lower extremities, with warm-up pheno-
menon, patient 5 manifested as HYPP without clinical history 
or signs of myotonia. Although the mutation p.A1156T has 
been described previously both in patients with HYPP and 
PMC,
15 it has never been associated with the pure myotonia 
phenotype, as in our patient 2. This phenotypic variability 
observed in individuals harboring the same SCN4A mutation 
strongly suggests that the genetic background-and perhaps 
other epigenetic factors-influences the clinical expression of 
particular mutations. 
The c.3917G>A (p.G1306E) mutation, located at the cyto-
plasmic linker between domains III and IV (ID3-4), was also 
found in two patients, in both of whom it manifested as pure 
myotonia (patients 1 and 6). This mutation had been reported 
in patients with PAM and has been functionally characteriz-
ed (Table 1, Figs. 1 and 2).
16,17 
Our study shows that SCN4A mutations produce different 
phenotypes of nondystrophic myotonia and periodic paraly-
sis syndrome. We have also shown that certain SCN4A mu-
tations may not be associated with specific clinical phenotypes, 
suggesting poor genotype-phenotype correlations in skeletal 
muscle sodium channelopathy. 
In sodium channelopathy, there is a group of patients who 
manifest with pure myotonia. These patients exhibit one of 
several clinical phenotypes including myotonia fluctuans, 
myotonia permanens, and acetazolamide-responsive myoto-
nia.
18 They are distinct from those with PMC by the absence 
of paradoxical myotonia and cold sensitivity. Since many such 
patients have myotonia that becomes much more pronounc-
ed after the ingestion of potassium-rich food, the condition 
has been collectively called PAM. However, some patients 
with SCN4A-related pure myotonia do not exhibit such po-
tassium sensitivity,
11,19 and thus the condition may be more ap-
propriately labeled sodium-channel myotonia. The myotonia 
in this group of patients is very similar to that observed in 
those with myotonia congenita (MC), and clinical differenti-
ation may not be possible. The four patients with pure myo-
tonia in our study had also initially been considered as having 
MC, but they were finally shown to have SCN4A mutations. 
A recent study involving the screening of SCN4A and CLCN1 
mutations in large numbers of patients with nondystrophic 
myotonia found that 20% of patients who had been clinically 
diagnosed as MC had SCN4A mutations.
20 
Our study also showed that sodium channelopathy com-
prises highly variable clinical phenotypes, and that the geno-
type-phenotype correlation is not unequivocal. Although care-
ful clinical evaluation is of great help, we suggest that a de-
finite molecular diagnosis using sequence analysis of both 
SCN4A and CLCN1 is essential for the differential diagnosis 
of sodium channelopathy from other conditions, especially 
when a patient presents with pure myotonia. 
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